|
|
|
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) |
|
|
|
| |
Alnylam Pharmaceuticals Inc Outlook |
On January 13 2025 the Alnylam Pharmaceuticals Inc provided following guidance
nnAlnylam Pharmaceuticals, Inc. Provides Preliminary 2024 Revenue Results and 2025 Forecast Alongside Pipeline Development Goalsnn
CAMBRIDGE, Massachusetts – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a trailblazer in the field of RNA interference (RNAi) therapeutics, has shared its preliminary results for global net product revenues for the fourth quarter and full year of 2024. The announcement highlights the financial performance of its key products: ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Moreover, the company has outlined its guidance for net product revenues in 2025, alongside its expectations for non-GAAP operating income and ambitious pipeline objectives.
Despite the absence of specific numerical targets or financial figures in this announcement, Alnylam's strategic commercial and clinical advancements throughout 2024 have set the stage for what the company anticipates will be a groundbreaking year ahead. The development and enhancement of its product lineup are indicative of the company’s commitment to addressing global health challenges and expanding access to innovative therapies for patients in need.
Alnylam’s focus on delivering impactful RNAi therapies has established the company as a leader in its industry, and the outlook for 2025 reflects strong confidence in sustained growth and innovation. The goals set forth not only demonstrate Alnylam’s dedication to its current portfolio but also indicate a robust pipeline poised to deliver future therapies that can enhance patient lives and generate substantial revenue.
As we move into the new year, stakeholders and industry observers will closely monitor Alnylam’s progress in achieving its outlined objectives and the implications for the company's trajectory in the competitive pharmaceutical landscape.,
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
